Bile ducts are slim tubes that carry a liquid called bile from your liver to the gallbladder and the small intestine. When cancer cells start forming in the bile ducts and destroying healthy cells, such a condition is called cholangiocarcinoma or bile duct cancer.
Bile duct cancer is a rare kind of cancer. It accounts for 10% to 20% of all liver cancers. Bile duct cancer might be rare. However, it is one of the most threatening types of cancer, responsible for many deaths worldwide.
Hence, it is necessary to get proper treatment in time.
Bile duct cancer may not have a cure, but it is possible to control the disease with timely and effective treatment. Lytgobi is one such treatment. We have covered this new treatment for bile duct cancer in depth.
More About New Treatment for Bile Duct Cancer
Lytgobi is a prescription drug used to treat bile duct cancer (intrahepatic cholangiocarcinoma) in adults with a specific type of abnormal FGFR2 gene.
Lytgobi was developed to treat bile duct cancer that has spread or cannot be eliminated by surgery. Lytgobi is a fibroblast growth factor receptor (FGFR) inhibitor that stops cancer cells from growing and multiplying.
It is preferred in patients who have already received previous treatment and whose tumor has a particularly unusual FGFR2 gene.
Oncologists will test your cancer for a specific abnormal FGFR2 gene and ensure that Lytgobi is right for you.
It has yet to be determined whether or not this medication is safe and effective in children.
What are its Side Effects?
Like any other treatment, this latest bile duct cancer treatment has adverse effects.
Regardless of how meager, you should know them!
The following are some of the known side effects of Lytgobi:
Note: There might be more side effects yet to be identified.
You should know many more before starting the new bile duct cancer treatment.
We have them curated.
So please pay attention!
Considerations for New Treatment for Bile Duct Cancer:
- Lytgobi is not suggested for pregnant women. It can harm your unborn baby or cause miscarriage.
- It is suggested not to breastfeed during and for one week after the treatment.
- It would help if you did not eat or drink grapefruit products during your treatment.
- If you vomit after taking one dose, do not take another. Administer regular dose the next day at the usual time.
- Tell your doctor immediately if you see any changes in your vision during treatment, such as blurred vision, flashes of light, or seeing black spots.
- It is suggested to take eye gels or artificial tears during treatment to prevent or treat dry eyes.
- Your doctor may prescribe changes in your diet, phosphate-lowering therapy, or change, interrupt, or stop treatment if needed.
- Tell your healthcare provider immediately if you develop muscle cramps, numbness, or tingling around your mouth.
References:
https://www.clinicaltrialsarena.com/comment/approval-lytgobi-cholangiocarcinoma/
https://www.curetoday.com/view/fda-approves-lytgobi-for-advanced-cholangiocarcinoma
